Navigation Links
BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
Date:3/11/2008

NOVATO, Calif., March 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jeff Cooper, Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 28th Annual Healthcare Conference in Boston on Tuesday, March 18, 2008 at 10:15 a.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R) and Naglazyme(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 24, 2017 , ... Center for Hispanic Leadership (CHL) Academy , the ... Chavez, Manager, Employee & Labor Relations at City of Hope , a world-renowned ... the Month. City of Hope is committed to stay out in front of its ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... focus of a new report from the Frank Hawkins Kenan Institute of ... Influential business leaders, academics and policy makers identified concrete solutions at the “What’s ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... Thrive , Well-meaning studies such as the Fordham Institute’s High Stakes for ... top students, such as including gifted or high-achieving students as a subgroup and ...
(Date:1/24/2017)... ... January 24, 2017 , ... The NewKILO JRP, a ... (NMIs) and co-funded by the European Union (EU), was completed in May 2015. The ... instead being maintained and used in air, which presents some challenges to establishing traceability ...
(Date:1/24/2017)... ... ... American Family Care (AFC) has opened a new 4,000+ square foot state-of-the-art ... the area. The Bedford clinic will be the nineteenth location opened by AFC in ... and Dr. Kristina Orio. Adams and Orio also independently own and operate AFC clinics ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , Jan. 24, 2017 Results show ... dose compared with linac-based radiotherapy platforms Elekta ... spares healthy brain tissue and delivers a higher radiation dose ... patients undergoing radiosurgery for large or complex brain tumors, were ... ...
(Date:1/24/2017)... -- www.Financialbuzz.com - The cannabis market ... the United States as eight more states had ... 64, the California Cannabis Legalization Initiative, was passed by a ... 2016. This outcome means that individuals in California ... certain amount of cannabis for personal use. According to a ...
(Date:1/24/2017)... SAN FRANCISCO , January 24, 2017 ... reach a value of USD 3.8 billion by 2025, ... Inc. The market growth can be attributed to the ... awareness about early diagnosis of micro calcifications in breast ... Cancer Foundation, CDC, and Breast Cancer Organization are promoting ...
Breaking Medicine Technology: